Marijuana Impact on Medicaid Act of 2026
Summary
S.4345 is an early-stage bill requiring HHS to study and report on Medicaid costs from marijuana-related hospital visits. It authorizes no funding, imposes no mandates, and has no direct market impact. No tickers meet the confidence gate for inclusion.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.4345 is a data-reporting bill with zero funding or regulatory impact.
- 2.No public company is directly affected; no tickers meet the confidence threshold.
- 3.The bill is in early stage with low momentum; market impact is negligible.
Market Implications
No market implications. The bill does not authorize spending, impose compliance costs, or create revenue opportunities for any publicly traded company. The healthcare sector is unaffected in the near term.
Full Analysis
On April 20, 2026, Senator Budd (R-NC) introduced S.4345, the Marijuana Impact on Medicaid Act of 2026. The bill was read twice and referred to the Senate Committee on Finance. It is in the earliest legislative stage with no committee hearings or markup scheduled. The bill directs the Secretary of Health and Human Services to collect data on federal and state Medicaid expenditures attributable to hospital and emergency room visits related to marijuana use, and to report findings and recommendations to Congress within one year of enactment. No funding is authorized or appropriated; the bill is purely a data-collection and reporting mandate. The only obligated party is HHS, which must compile existing claims data. No private company is directly affected. The bill has two cosponsors (Sen. Ricketts) and no companion bill in the House. Legislative momentum is low given the sponsor's junior status and the bill's procedural nature. Even if enacted, the report would not change any company's revenue, costs, or competitive position. The healthcare sector is listed as affected because the policy area is health, but no specific company is impacted.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Veterans SPORT Act
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.